Browsing by Author "Turan, ÖF"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
    Koç, S; Sen, S; Terzi, Y; Kizilay, F; Demir, S; Aksoy, DB; Kurtulus, F; Bilge, N; Idilman, E; Uzunköprü, C; Güngör, S; Çilingir, V; Ethemoglu,Ö; Boz, C; Gümüs, H; Kiliç, AK; Kisabay, A; Bir, LS; Turan, ÖF; Soysal, A; Köseoglu, M; Uzuner, GT; Bayindir, H; Kabay, SC; Çam, M; Yayla, V; Tan, HY; Özcan, A; Taskapioglu,Ö; Korkmaz, M; Tamam, Y; Inanç, Y; Efendi, H; Kotan, D; Yetkin, MF; Bilgiç, AB; Saçmaci, H; Demirci, S; Çelik, Y; Poyraz, T; Terzi, M
    Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz May & imath;s University's Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.